14.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.21
Offen:
$14.2
24-Stunden-Volumen:
515.70K
Relative Volume:
0.37
Marktkapitalisierung:
$11.89B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
21.67
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
+0.78%
1M Leistung:
-2.93%
6M Leistung:
+9.96%
1J Leistung:
-13.69%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.24 | 11.83B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
ZTS
Zoetis Inc
|
155.37 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.86 | 46.99B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.71 | 43.17B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.05 | 20.82B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
305.35 | 13.98B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
2023-01-30 | Eingeleitet | JP Morgan | Underweight |
2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
2020-09-18 | Hochstufung | Investec | Sell → Hold |
2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
2019-06-11 | Eingeleitet | Barclays | Equal Weight |
2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Validea's Top Health Care Stocks Based On Peter Lynch7/28/2025 - Nasdaq
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
From Infosys, IndusInd Bank to Natco Pharma, 9 stocks to watch today - financialexpress.com
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Q1 Results Highlights: Infosys net profit rises 9%, Tata Consumer revenue jumps 10% - Moneycontrol
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley initiates coverage on Dr. Reddy’s stock with Equalweight rating - Investing.com India
Dr Reddy's Laboratories among four key stocks to trade ex-dividend today - Mint
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
Trump Tariffs: Dr Reddys To Lupin — Pharma Stocks To Be In Focus After Threat Of 200% Levies - NDTV Profit
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):